All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Uptake of New Therapies Pushes Treatment Paradigm Forward in Breast Cancer

April 22nd 2022

Recent developments across the breast cancer paradigm include the utilization of trastuzumab deruxtecan in patients with metastatic HER2-positive breast cancer, plus neoadjuvant treatment strategies in triple-negative breast cancer.

FDA Grants Orphan Drug Designation to Toripalimab for Small Cell Lung Cancer

April 21st 2022

The FDA has granted an orphan drug designation to the PD-1 inhibitor toripalimab as a potential therapeutic option for patients with small cell lung cancer.

FDA Grants Fast Track Designation to CMG901 in Relapsed/Refractory Metastatic Gastric/GEJ Cancer

April 21st 2022

The FDA has granted a fast track designation to the antibody-drug conjugate CMG901 as a single-agent treatment for patients with unresectable or metastatic gastric and gastroesophageal junction cancer that is relapsed or refractory to approved therapies.

ODAC Unanimously Votes to Recommend Randomized Data for Approval of PI3K Inhibitors in Hematologic Cancers

April 21st 2022

In a 16 to 0 vote, with 1 abstention, the FDA’s Oncologic Drugs Advisory Committee voted in support of basing future approvals for PI3K inhibitors on randomized data instead of single-arm clinical trials.

KIN-3248 Under Exploration in Advanced Solid Tumors Harboring FGFR2 and/or FGFR3 Alterations

April 21st 2022

The safety, tolerability, and preliminary efficacy of the irreversible, small molecule pan-FGFR inhibitor KIN-3248 is under investigation in adult patients with advanced tumors harboring FGFR2 and/or FGFR3 gene alterations, as part of the phase 1 KN-4802 trial.

John Theurer Cancer Center Investigators Confirm that Preserved Stem Cells Are Safe and Effective for Multiple Myeloma Treatment Up to 20 Years Later

April 21st 2022

Investigators from Hackensack University Medical Center’s John Theurer Cancer Center confirm that cryopreserved stem cells collected before a first stem cell transplant to treat multiple myeloma are just as viable and potent for use in a second "salvage" transplant 20 years later.

Eligibility Criteria of Pancreatic Cancer Trials Perpetuate Disparities in Black Patient Participation

April 21st 2022

Traditional eligibility criteria for pancreatic cancer clinical trials reinforce underrepresentation of racial and ethnic minorities in clinical trial candidacy and skew standards of care in favor of non-Hispanic White participants.

Nivolumab Plus Relatlimab Aims to Become Primary Treatment Option for Advanced Melanoma

April 21st 2022

The addition of novel anti–LAG-3 antibody relatlimab-rmbw to antiPD-1 antibody nivolumab offers treatment-naïve patients with unresectable or metastatic melanoma an efficacious and tolerable immunotherapy treatment option.

Personalized Medicine Evolves With CDK4/6 Inhibitors, Immunotherapy, and ADCs in Breast Cancer

April 21st 2022

Hadeel Assad, MD, discussed how CDK4/6 inhibitors have been implemented into practice and provided updates on key clinical trials in HER2-positive breast cancer and triple-negative breast cancer.

FDA Grants Fast Track Designation to ADI-001 in Relapsed/Refractory Non-Hodgkin Lymphoma

April 20th 2022

The FDA has granted a fast track designation to the CAR T-cell therapy ADI-001 for the treatment of patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

Pembrolizumab/Lenvatinib Plus Chemo May Represent “Powerful” Option for NSCLC

April 20th 2022

Roy S. Herbst, MD, PhD, discusses the rationale for exploring immunotherapy/TKI combinations like pembrolizumab plus lenvatinib in patients with non–small cell lung cancer, and outlined the different efforts that comprise the LEAP clinical trial program.

PROBE Trial in Progress to Understand Potential Benefits of Cytoreductive Nephrectomy in Metastatic RCC

April 20th 2022

Ulka Nitin Vaishampayan, MBBS, discusses the intent of the PROBE trial, as well as updates regarding the KEYNOTE-564 trial and novel agents in kidney cancer treatment.

Trimodality Approach to MIBC Paves Path for Bladder Preservation

April 20th 2022

Standard chemoradiation therapy regimens have had marked success for patients with muscle-invasive bladder cancer; however, up to 30% of patients who receive treatment with bladder preserving intent will have recurrence.

Prominent Local Cancer Surgeon Rebecca Edmonds, MD, Joins AHN

April 20th 2022

Rebecca D. Edmonds, MD, a surgical oncologist specializing in the treatment of diseases of the liver, pancreas, gallbladder, spleen, colon, thyroid and breast, has joined the Allegheny Health Network Cancer Institute.

War Is the Wrong Metaphor for Cancer Care

April 20th 2022

The National Cancer Act of 1971 introduced the concept of a “war on cancer” and forever changed the way we discuss the disease.

Pragmatic Clinical Trials Can Play a Key Role in Oncology

April 20th 2022

Pragmatic clinical trials “inform a clinical or policy decision by providing evidence for adoption of the intervention into real-world clinical practice.”

A Wealth of Clinical Trials Pushes the Treatment Landscape Forward Across Lung Cancer

April 20th 2022

David P. Carbone, MD, PhD, discusses the evolution of immunotherapy and targeted therapy in non–small cell lung cancer and the importance of biomarker testing for personalized therapy.

Tislelizumab/Chemo May Become Frontline SOC for Recurrent/Metastatic Nasopharyngeal Cancer

April 19th 2022

The combination of tislelizumab and gemcitabine/cisplatin continued to demonstrate a greater progression-free survival benefit than chemotherapy alone when used in the frontline treatment of patients with recurrent or metastatic nasopharyngeal cancer.

HER2-Targeted CAR Macrophage CT-0508 Under Exploration in Solid Tumors with HER2 Overexpression

April 19th 2022

The safety, tolerability, and preliminary efficacy of the anti-HER2 CAR macrophage therapy, CT-0508, will be investigated in patients with solid tumors and HER2 overexpression, as part of a first-in-human phase 1 study.

Tebentafusp Offers Path Forward in the Uveal Melanoma Treatment Landscape

April 19th 2022

Marlana M. Orloff, MD, overviews how pivotal efficacy and safety data of tebentafusp will improve the treatment paradigm for adult patients with HLA-A*02:01–positive unresectable or metastatic uveal melanoma.